Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Divaya Bhutani, Shami Chakrabarti, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Markus Mapara, Abhinav Deol, Joseph Uberti, Ran Reshef

Blood (2025) 146 (Supplement 1): 4062.

https://doi.org/10.1182/blood-2025-4062

Published: 2025

Journal Articles

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Josefine Krüger, Shirong Li, Guifen Liu, Yuen Lam Dora Ng, Michael Hughes, Rajshekhar Chakraborty, Divaya Bhutani, Jan Krönke, Suzanne Lentzsch, Jing Fu

Blood (2025) 146 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2025-2150

Published: 2025

Journal Articles

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

Divaya Bhutani, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Samuel Pan, Shayan Shirazayan, Sherley Mejia, Naomi Sender, Elizabeth Shelton, Meghan Sise

Blood (2025) 146 (Supplement 1): 579.

https://doi.org/10.1182/blood-2025-579

Published: 2025

Journal Articles

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering, Adam Rosenthal, J Christine Ye, Prashant Kapoor, Saad Usmani, Manisha Bhutani, S. Vincent Rajkumar, Paul Gater, Robert Orlowski

Blood (2025) 146 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2025-1840

Published: 2025

Journal Articles

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Samuel Rubinstein, Yusha Liu, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Jing Christine Ye, Divaya Bhutani

Blood (2025) 146 (Supplement 1): 3973.

https://doi.org/10.1182/blood-2025-3973

Published: 2025

Journal Articles

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Simon Zhen, Divaya Bhutani, Mathew Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Hughes, Jai Radhakrishnan, Markus Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5740.

https://doi.org/10.1182/blood-2025-5740

Published: 2025

Journal Articles

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Michael Hughes, Yiran Peng, Shikun Wang, Andrew Laine, Jai Radhakrishnan, Metodi Balev, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2025-5756

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Long-term follow-up of venetoclax therapy in AL amyloidosis

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Michael Hughes, Michaela Liedtke, Jeffrey Zonder, Mansen Yu, Anita D'Souza

Blood (2025) 146 (Supplement 1): 7497.

https://doi.org/10.1182/blood-2025-7497

Published: 2025

Journal Articles

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Divaya Bhutani, Samuel Rubinstein, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Lu Dai, Micah Richardson, J Christine Ye

Blood (2025) 146 (Supplement 1): 2194.

https://doi.org/10.1182/blood-2025-2194

Published: 2025

Journal Articles

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Abdul-Hamid Bazarbachi, HuiHui Ma, Simon Zhen, Miriam Klahr, Diane M. George, Christian Gordillo, Samuel Pan, Amer Assal, Andrew Eisenberger, David Diuguid, Ran Reshef, Suzanne Lentzsch, Divaya Bhutani, Rajshekhar Chakraborty, Monica Bhatia, Markus Mapara

Blood (2025) 146 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2025-4255

Published: 2025

Journal Articles

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah A. M. Cuddy, Rodney H. Falk, Suzanne Lentzsch, Jacob P. Laubach, Giada Bianchi

Blood (2025) 146 (16): 1929–1935.

https://doi.org/10.1182/blood.2025028383

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, J Christine Ye, Samuel M. Rubinstein, Sascha Tuchman, Eben I Lichtman

Blood (2024) 144 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2024-210587

Published: 2024

Journal Articles

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2024) 144 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2024-209301

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Meghan Sise, Elizabeth Shelton, Emily Simone, Naomi Sender, Sherley Mejia, Shayan Shirazayan

Blood (2024) 144 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2024-210308

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Long-term follow-up of venetoclax therapy in AL amyloidosis

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only